Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Conditions

• Erythematous Rosacea

Interventions

• DRUG: 0.18% COL-118 facial gel (1.8 mg brimonidine)
• DRUG: 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)
• DRUG: Advanced Eye Relief
• DRUG: COL-118 facial gel vehicle

Sponsor

Galderma R&D